BCA
ORIC icon

Berman Capital Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Berman Capital Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2K Buy
+113
New +$2.29K ﹤0.01% 1721

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's ORIC Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Oric Pharmaceuticals (ORIC) in Q3 2021: 113 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1721 among its holdings.

82 funds tracked by Wall St. Rank hold ORIC as of Q3 2021.

  • Berman Capital Advisors held 113 shares of Oric Pharmaceuticals worth $2K as of Q3 2021.
  • Oric Pharmaceuticals was a new Berman Capital Advisors position in Q3 2021.
  • Oric Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1721 holding.
  • 82 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.